What's Next? Trends and Opportunities in the Italian Pharmaceutical Industry.

Trends and opportunities in the Italian pharmaceutical industry, an overview of the market in the five-year period 2021-2026.

Market Analysys

The Italian pharmaceutical market has been on a downward trend in recent years, registering steady growth in 2017, only to have a decline in 2019.

In 2021, the Italian pharmaceutical sector grew by 0.8%, registering a negative trend and weak growth due to the impact of the COVID-19 pandemic. The market grew in 2022 and is expected to grow slowly until 2025.

Unlike many other businesses and industries around the world that have suffered severe disruptions due to the COVID-19 pandemic, the pharmaceutical market has performed relatively well. Although nationwide closures and border restrictions have caused some supply problems, most companies hold significant inventories to cope with such situations. In addition, some of the major pharmaceutical companies, have received significant public and private investment to facilitate the development of vaccines that can protect against the virus and control its spread, which has likely offset the losses caused by the disruption of supply chains. This means that the COVID-19 pandemic had a relatively minimal impact on the Italian pharmaceutical market.

Italy has a 7.8% share of the European pharmaceutical market and was the fourth largest market in Europe in 2021.

The market trend is expected to have a projected CAGR of 0.9% in 2021-26, which is expected to bring the market to a value of $27.6 billion by the end of 2026. In comparison, the French and German markets will grow with a CAGR of 3% and 5.1% respectively over the same period, to reach respective values of $84.3 and $102.7 billion in 2026.

The market has been somewhat supported by Italy's aging population and the increase in age-associated diseases, such as diabetes and cardiovascular disease. Italy has one of the oldest populations in the world, with an average age of about 47.2 years. Nearly 48% of the population is aged 18 to 69 years and older, of which 32.8% are older than 64 years. This trend will continue to drive demand for pharmaceuticals in the long run, which could help the market withstand further decline.

...